MS4A1 and diffuse large B-cell lymphoma: Grigg et al. analyzed 41 patients with r/r DLBCL and PMBCL following Glofitamab treatment after a median of three previous lines of therapy and found that at the moment of relapse, the rate of CD20 loss at progression was 59%, with a median OS of 4.1 months after relapse [80,98].